Inside Secrets to Angel and Crowdfund Investing | Karen Rands, Ep 47
Episode Summary
Karen Rands, founder of the Compassionate Capitalist Movement, discusses how individuals can build wealth by investing in entrepreneurs through angel investing and equity crowdfunding. She shares her journey from IBM intrapreneur to angel investor advocate, explains revenue-share investment models as alternatives to traditional equity deals, and outlines strategies for building diversified portfolios that generate both financial returns and social impact.
Pull Quotes
“I am disrupting how people think about creating wealth, and that is by learning how to invest in entrepreneurs as an asset class, to invest with impact and purpose, and make a difference by funding innovations that you care about.”
“VCs have all the money in the world and the resources to be able to get it right. And they can't even get it right cause they're the ones that create the model or the paradigm that it's out of 10 investments. You're going to have one that hits 10X.”
On her failed healthcare software startup
“Without capital, that solution is still out there. If somebody wants to pick that software up and run with it, he would probably sell it for really cheap because he never got that company built because he couldn't get funding.”
On discovering angel investing for the first time
“I walked in there, and it was like, oh my God, look at this, this is a group that really are the ones that get to decide what innovation gets to market. What innovation do we have to solve the problems of our world or the problems we care about, because without capital, that solution, that guy, that solution is still out there.”
“The reality with the stock market is that you're transacting with another stockholder, the company other than, and it's always, you know, somebody is selling, somebody is buying. Investing in entrepreneurs is the most direct way to have an impact.”
Transcript
Todd Merrill:
Hi, welcome to Tales from the SkyLounge. It's a podcast about business, consulting, and venture investing. We get out there in the world, we talk to people who are making it happen, and we get their stories. And if you could like and subscribe, our producer, James, would be very happy about that.
Today's guest in the SkyLounge, Karen Rands. Hi, Karen.
Karen Rands:
Hello there, Todd. Happy to be here. Excited to be here today.
Want to go deeper?
Work With MeRelated Episodes
Founders: These Are the Mistakes You Don't Know You're Going to Make | Steve Walsh, Ep 52
Steve Walsh, an angel investor and startup advisor, shares lessons from 25 years building multi-billion dollar B2B divisions at Cox and Comcast before transitioning to helping early-stage founders. He discusses common founder mistakes, when to raise capital, the importance of customer validation before building product, and how he filters 6,000 conversations down to 69 investments through rigorous vetting and founder education.
The CEO Is the Salesperson: Why Founders Can't Hand Off the Pitch | Jen Bonnett, Ep 49
Jennifer Bonnett, a longtime tech entrepreneur and former ecosystem builder at ATDC and Invest Atlanta, discusses her transition back into technology through AI experimentation. She shares lessons from building a search engine in 1997, her current work vibe coding consumer apps with Claude, and her philosophy that CEOs must personally sell for at least the first year before delegating. The conversation explores how AI is lowering barriers to entrepreneurship while emphasizing that founders still need strong networks, customer discovery skills, and the discipline to market early.
A Trauma Surgeon and Entrepreneur on Healthcare, AI and What's Next | Niral Shah, Ep 44
Niral Shah, a trauma surgeon and serial entrepreneur, discusses his journey from starting a search engine startup during the dot-com boom to returning to medicine and now investing in healthcare innovation. He shares lessons from shutting down his first company responsibly, explains why healthcare represents 18-21% of US GDP with poor outcomes, and identifies opportunities in AI-driven biotech, disintermediation of healthcare delivery, and multiomic drug discovery targeting aging as a treatable condition.